To evaluate coordinate changes in CLU expression and autophagy activation after anticancer treatment, levels of CLU and markers of autophagy were initially defined in prostate cancer PC3 cells treated with several known autophagy-inducing agents, including inhibitors of the proteasome (MG132), mTOR (rapamycin) and AKT (AZD5363). This evidence concerns the gene CLU and prostate carcinoma.